DUAL SPECIFICITY PROTEIN KINASE TTK INHIBITOR MARKET ANALYSIS

Dual Specificity Protein Kinase TTK Inhibitor Market, By Product Type (S 81694, BAY 1217389, BOS-172722, CFI-402257, Others), By Application (Non-haematologic Malignancies, Breast Cancer, Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Others), By End User (Hospitals, Specialty Clinics, Others (Cancer Research Institutes, etc.)), By geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global Dual Specificity Protein Kinase Ttk Inhibitor Market: Key Developments

In November 2022, Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for cancer, announced a presentation for CFI-402411, an oral inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), a negative regulator of immune cell activation, at the 37^th Society for Immunotherapy of Cancer (SITC) Annual Meeting being held virtually and in person from November 8-12, 2022, at the Boston Convention and Exhibition Center in Boston.
In February 2022, Brickell Biotech, Inc., a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, acquired exclusive global rights to develop and commercialize a portfolio of novel, potent, and orally available stimulator of interferon genes (STING) inhibitors from Carna Biosciences, Inc., which have the potential to treat autoinflammatory disorders such as systemic lupus erythematosus and rheumatoid arthritis, rare genetic interferonopathies, and potentially other diseases.
In January 2020, TIO Bioventures, an emerging life science venture creation fund with a mission to build companies with innovative anti-cancer therapies, announced the launch of Treadwell Therapeutics.